Related Experiment Videos
Summary
Hormonal therapy remains crucial for advanced breast cancer patients, even with chemotherapy advancements. This approach offers significant benefits and survival improvements, regardless of receptor status or disease site.
Area of Science:
- Oncology
- Endocrinology
Background:
- Chemotherapy response rates have led to decreased use of hormonal therapy for advanced breast cancer.
- Estrogen and progesterone receptor assays influence decisions regarding hormonal therapy, often limiting its use when negative.
Purpose of the Study:
- To advocate for the continued use of additive hormonal therapy in advanced breast cancer management.
- To present a review of various hormonal agents and their role in treatment.
- To emphasize the benefits of hormonal therapy irrespective of receptor assay results or disease location.
Main Methods:
- Review of hormonal agents including estrogen, androgens, progestins, Teslac, and corticosteroids.
- Discussion of additive hormonal therapy, used alone or in combination with other treatments.
- Consideration of minimal restrictions based on hormonal assays or disease sites.
Main Results:
- Hormonal therapy, when positive on receptor assays, has shown renewed enthusiasm.
- Negative receptor assays have historically limited further consideration of hormonal therapy.
- Additive hormonal therapy demonstrates ease of administration and improved survival in responders.
Conclusions:
- Additive hormonal therapy should be employed for nearly all advanced breast cancer patients.
- Hormonal therapy, alone or combined, plays a significant role in managing advanced breast cancer.
- The benefits of hormonal therapy, including survival advantages, support its continued use.